[Cost-effective analysis evaluation of galcanezumab (Emgality)]
Academic Group of Cost-effectiveness Evaluation in Japan
Record ID 32018005318
Original Title: ガルカネズマブ (エムガルティ) に関する公的分析結果
Authors' objectives: The academic group reviewed the report on additional benefits and cost-effectiveness of galcanezumab for prevention of migraine submitted by the manufacturer (Eli Lilly Japan K.K.). This report summarizes the results of the review and the re-analysis by the academic group.
Authors' results and conclusions: Galcanezumab resulted in incremental cost-effectiveness ratios (ICER) of JPY 11,060,803, 5,371,334, 5,741,268, and 3,459,856/QALY for the target populations (a), (b), (c), and (d), respectively. In conclusion, the ICER for the target population (a) is likely to be over JPY 10 million/QALY, the ICERs for the target population (b) and (c) are likely to fall between JPY 5 and 7.5 million/QALY respectively, and between JPY 2 and 5 million/QALY for the target population (d).
Project Status: Completed
URL for project: https://c2h.niph.go.jp/
Year Published: 2023
URL for published report: https://c2h.niph.go.jp/en/results/C2H2101.html
English language abstract: An English language summary is available
Publication Type: Full HTA
- Cost-Effectiveness Analysis
- Antibodies, Monoclonal, Humanized
- Migraine Disorders
- cost-effectiveness analysis
- health technology assessment
Organisation Name: Center for Outcomes Research and Economic Evaluation for Health
Contact Address: 2-3-6 Minami, Wako-shi, Saitama 351-0197 Japan
Contact Name: Takeru Shiroiwa
Contact Email: firstname.lastname@example.org
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.